To improve individualized therapy, new prognostic and predictive markers are needed to identify patients with expected poor breast cancer outcome and patients who profit most from a given treatment. NF-κB pathway plays a pervasive role in the pathogenesis of cancer through its implication in distinct hallmarks of tumorigenesis. Previous studies have indicated the role of NF-κB transcription factor in promoting cell survival and resistance to chemotherapy in breast carcinoma. We have previously found that NQO1-rs1800566 predicts poor survival among breast cancer patients, particularly after anthracycline-based adjuvant chemotherapy and in patients with p53-aberrant tumors. We have also reported the inverse relationship between NQO1 protein expression and NF-κB activation. We have here analyzed the interaction of SNPs residing within the NF-κB signaling pathway genes, and NQO1-rs6499255 (tagging NQO1-rs1800566 with r2> 0.90) on breast cancer patient survival and treatment outcome. The panel of markers included the NF-κB pathway SNPs available in a custom Illumina iSelect genotyping array designed for Collaborative Oncological Gene-Environment Study (iCOGS) as well as NQO1-rs6499255. For the SNP-SNP interaction analysis on patient survival we conducted a likelihood ratio test that compares Cox's regression model with and without an interaction term to evaluate whether the interaction model is a better fit for the prognostic data. The results obtained from this study will be reported. Identification of interactive SNPs/genes contribute to the elucidation of the mechanisms underlying complex diseases such as breast cancer.

Citation Format: Maral Jamshidi, Rainer Fagerholm, Sofia Khan, Kristiina Aittomäki, Carl Blomqvist, Marjanka K. Schmidt, Heli Nevanlinna, BCAC: Breast Cancer Association Consortium. SNP-SNP interaction analyses of NQO1 and NF-κB signaling pathway genes on breast cancer survival and treatment outcome. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3274. doi:10.1158/1538-7445.AM2014-3274